ODAC Will Review Denosumab SRE Data If FDA Requires Advisory Committee

FDA's Oncologic Drugs Advisory Committee will take the lead in reviewing Amgen's osteoporosis drug Prolia (denosumab) for prevention of skeletal-related events in advanced cancer patients if the agency chooses to take the drug to panel